Targeting STAT3 Signaling for Immune Checkpoint Blockade to Augment PARP Inhibitor Therapy in BRCA-Mutated Ovarian Cancer PARP inhibitors and immune checkpoint inhibitors are two promising new therapies for ovarian cancer patients who have mutations in the BRCA gene. BRCA-mutated ovarian cancer cells produce a protein called PD-L1 to avoid being recognized and killed by immune […]
Read More
Weei-Chin Lin, MD, PhD Baylor College of Medicine Houston, Texas Novel approaches to target MYC in ovarian cancer Many ovarian cancers express the cancer-causing MYC protein at unusually high levels. The activation of MYC is a hallmark of cancer initiation, progression, and resistance to therapy. Unfortunately, MYC is one of the most difficult proteins to […]
Read More
Combining MEK inhibition with oncolytic viral therapy as a novel treatment for low grade serous ovarian carcinoma Low grade serous ovarian cancer (LGSC) is a rare form of ovarian cancer accounting for about 5% of ovarian cancer cases. While LGSC grows relatively slowly, it is stubbornly resistant to almost all therapeutics. As a result, outcomes […]
Read More
Multimodal single-cell surfaceome and transcriptome profiling of longitudinal high-grade ovarian cancer ascites samples Despite advances in the initial treatment of high-grade serous ovarian cancer (HGSOC), recurrence of the disease is very common and effective treatment of recurrent HGSOC remains a major challenge. In order for a tumor to gain resistance to chemotherapy and progress into […]
Read More
Using genetic predictors of CA125 to improve personalized ovarian cancer screening Most ovarian cancer cases are currently diagnosed at late stage when less than half of the women will live five years after their diagnosis. In contrast, ovarian cancer cases diagnosed at an early stage have more than 90% living after five years from diagnosis. […]
Read More